Cognito Therapeutics has presented new data demonstrating its Spectris neuromodulation device’s potential to slow cognitive decline and preserve white matter in patients with mild to moderate ...
Cognito Therapeutics, a neurotechnology company advancing disease-modifying therapies to treat CNS diseases, today announced the publication of a study in Alzheimer's & Dementia: Translational ...
Spectris AD™ meaningfully reduced functional and cognitive decline in Alzheimer’s Disease over 6 months compared to sham treatment and was associated with 60-84% time savings. OVERTURE I Phase 2 MRI ...
Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced new data from its OVERTURE feasibility trial at the AD ...
Cognito Therapeutics, a clinical-stage neurotechnology company pioneering neuromodulation-based treatments for neurodegenerative diseases, announced five new poster presentations at the Alzheimer’s ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cognito Therapeutics, a pioneering neurotechnology company developing disease-modifying therapies for neurodegenerative diseases, today announced key executive ...
AI reveals genetic links in aging, chronic diseases, and lifestyle factors across nine organ systems
A recent study published in the journal Nature Aging investigated the genetic architecture of artificial intelligence (AI)-derived biological age gaps (BAGs) for multiple organ systems and their links ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback